AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 2589659
Drug: Oral cyclosporine
RxNorm normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral cyclosporine (CYS) given less than 4 hours preoperatively
Trial: 2589659
Drug: Oral cyclosporine
RxNorm normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral cyclosporine (CYS) given greater than 7 hours preoperatively
Trial: 7002354
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Persantine and aspirin
Trial: 19995094
Drug: Prulifloxacin 600
RxNorm normalized name: Orbifloxacin
DrugBank: Orbifloxacin (DB11443)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prulifloxacin 600 mg
Trial: 7014694
Drug: Silver sulfadiazine
RxNorm normalized name: Silver Sulfadiazine
DrugBank: Silver sulfadiazine (DB05245)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Silver sulfadiazine cream (15 patients)
Trial: 7014694
Drug: Povidone-iodine solution
RxNorm normalized name: POVIDONE-IODINE 1 g in 100 mL TOPICAL LIQUID [Loris Povidone-Iodine Solution]
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Povidone-iodine solution (11 patients)
Trial: 21445638
Drug: Zofenopril 30
RxNorm normalized name: zofenopril 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zofenopril 30 mg/day
Trial: 1663914
Drug: Baclofen (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baclofen (10 mg)
Trial: 27184170
Drug: Alirocumab 75
RxNorm normalized name: alirocumab 75 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alirocumab 75 mg
Trial: 26608067
Drug: Ramipril (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ramipril (5 mg orally twice daily)
Trial: 23885048
Drug: High-dose vitamin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose vitamin D (5000 IU/d)
Trial: 20950224
Drug: Certoparin 3000
RxNorm normalized name: certoparin
DrugBank: Certoparin (DB09261)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Certoparin 3000 IU daily
Trial: 20950224
Drug: Unfractionated Heparin
RxNorm normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Unfractionated Heparin (UFH) 7500 IU twice daily
Trial: 12370595
Drug: Pulmonary rehabilitation
RxNorm normalized name: Lobaria pulmonaria extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pulmonary rehabilitation program (twice a week for 6 weeks)
Trial: 2012462
Drug: High-dose ketoconazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose ketoconazole (800 mg/kg per day, orally)
Trial: 2012462
Drug: Amphotericin B
RxNorm normalized name: Amphotericin B
DrugBank: Amphotericin B (DB00681)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amphotericin B (0.5 mg/kg per day, intravenously)
Trial: 14511998
Drug: Antiplatelet agents
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiplatelet agents (aspirin, 325 mg once daily or ticlopidine, 250 mg twice daily)
Trial: 12947997
Drug: Nasal immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal immunotherapy
Trial: 10867377
Drug: Bronchial immunotherapy
RxNorm normalized name: Bronchitol
DrugBank: Mannitol (DB00742)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bronchial immunotherapy
Trial: 1335651
Drug: Hepatitis A
RxNorm normalized name: HEPATITIS A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hepatitis A vaccine (SmithKline Beecham Biological), vaccination schedule of 0, 1 and 2 months with a booster at month 12
Trial: 1335651
Drug: Hepatitis A
RxNorm normalized name: HEPATITIS A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hepatitis A vaccine (SmithKline Beecham Biological), vaccination schedule of day 0 and 14 with a booster at month 7
Trial: 29785045
Drug: Functional electrical
RxNorm normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Functional electrical stimulation (FES) therapy (50 Hz/500 µs) for 4 weeks, with two weekly sessions lasting 15 minutes each, intensity lower than the motor threshold.
Trial: 29785045
Drug: Placebo FES
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo FES treatment following the same routine as the IG.
Trial: 26946725
Drug: Ginger-partition moxibustion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ginger-partition moxibustion combined with glucocorticoid (methylprednisolone 24 mg daily, tapering down over 6 weeks)
Trial: 26946725
Drug: Simple oral
RxNorm normalized name: Simple Oral Syrup
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simple oral glucocorticoid (methylprednisolone 24 mg daily, tapering down over 6 weeks)
Trial: 23712600
Drug: niacin/laropiprant (1000/20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: niacin/laropiprant (1000/20 mg daily for 4 weeks and 2000/40 mg daily thereafter)
Trial: 17913310
Drug: High dosage
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dosage trivalent influenza vaccine (60 microg of HA for each component)
Trial: 17913310
Drug: Licensed vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Licensed vaccine (15 microg of HA for each component)
Trial: 11910662
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg estradiol + 5 mg dydrogesterone
Trial: 11910662
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg estradiol + 10 mg dydrogesterone
Trial: 2298969
Drug: Intralesional cyclosporine
RxNorm normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intralesional cyclosporine administered three times weekly for 4 weeks
Trial: 6110570
Drug: Saline infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline infusion (in vitro)
Trial: 28223373
Drug: NICU-based interventions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NICU-based interventions (including cognitive behavioral therapy)
Trial: 28223373
Drug: Cognitive behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavioral therapy interventions
Trial: 23280223
Drug: Nifedipine (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine (80 mg/d for 12 days)
Trial: 20147572
Drug: Diazepam 30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diazepam 30 mg
Trial: 20147572
Drug: Levetiracetam 4000
RxNorm normalized name: Levetiracetam
DrugBank: Levetiracetam (DB01202)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Levetiracetam 4000 mg
Trial: 20147572
Drug: Diphenhydramine 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diphenhydramine 400 mg
Trial: 20147572
Drug: Valproic acid
RxNorm normalized name: Valproic Acid
DrugBank: Valproic acid (DB00313)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Valproic acid 1500 mg
Trial: 19931753
Drug: Enzyme-assisted subcutaneous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enzyme-assisted subcutaneous infusion (EASI) with 1-mL injection of 150 U of human recombinant hyaluronidase, followed by 250 mL D5NS infusion.
Trial: 19931753
Drug: Standard intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard intravenous (IV) access with 20-gauge IV placement and 250-mL maximal-rate IV bolus of normal saline.
Trial: 9059944
Drug: Two injections
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two injections of inactivated hepatitis A vaccine (25 Units) at 0 and 6 months (group A)
Trial: 9059944
Drug: Three injections
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three injections of inactivated hepatitis A vaccine (25 Units) at 0, 2, and 6 months (group B)
Trial: 3891616
Drug: Tyrosine supplementation
RxNorm normalized name: Tyrosine
DrugBank: Tyrosine (DB00135)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tyrosine supplementation (2.5 g t.i.d.)
Trial: 29582077
Drug: intervention patients
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intervention patients (free tobacco treatment)
Trial: 29582077
Drug: control patients
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: control patients (treatment recommendations)
Trial: 20143466
Drug: Preoperative TCF
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative TCF (docetaxel 75 mg/m(2) day 1, cisplatin 75 mg/m(2) day 1, and fluorouracil 300 mg/m(2) per day for days 1‐14)
Trial: 11966889
Drug: Vital pulp
RxNorm normalized name: acai fruit pulp
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vital pulp therapy with PGE2 measurement
Trial: 11805612
Drug: Sygen® treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sygen® treatment (specific dosage and duration not mentioned)
Trial: 9922519
Drug: Mérieux vaccine,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mérieux vaccine, 0.1 ml
Trial: 9922519
Drug: Tokio vaccine,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tokio vaccine, 0.1 ml
Trial: 9922519
Drug: Mérieux vaccine,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mérieux vaccine, 0.05 ml
Trial: 9922519
Drug: Tokio vaccine,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tokio vaccine, 0.05 ml
Trial: 7620239
Drug: Salbutamol (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salbutamol (5 mg)
Trial: 30135556
Drug: Venlafaxine-XR-plus-mirtazapine combination
RxNorm normalized name: venlafaxine Extended Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Venlafaxine-XR-plus-mirtazapine combination
Trial: 30135556
Drug: Bupropion-plus-escitalopram combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupropion-plus-escitalopram combination
Trial: 30135556
Drug: Escitalopram monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Escitalopram monotherapy odds ratio
Trial: 30135556
Drug: Venlafaxine-plus-mirtazapine combination
RxNorm normalized name: Mirtazapine
DrugBank: Mirtazapine (DB00370)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Venlafaxine-plus-mirtazapine combination odds ratio
Trial: 30135556
Drug: Bupropion-plus-escitalopram combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupropion-plus-escitalopram combination odds ratio
Trial: 28454823
Drug: Inhaled nitric
RxNorm normalized name: nitric oxide Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled nitric oxide (NO) plus oxygen
Trial: 18451387
Drug: Five weekly
RxNorm normalized name: fivehorn smotherweed pollen extract
DrugBank: Bassia hyssopifolia pollen (DB10941)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Five weekly intra-articular injections of sodium hyaluronate
Trial: 18451387
Drug: Three weekly
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three weekly intra-articular injections of sodium hyaluronate followed by two weekly intra-articular injections of saline solution
Trial: 18451387
Drug: Five weekly
RxNorm normalized name: fivehorn smotherweed pollen extract
DrugBank: Bassia hyssopifolia pollen (DB10941)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Five weekly intra-articular injections of saline solution
Trial: 16824849
Drug: Heparin plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin plus planned GPIIb/IIIa blockade
Trial: 16824849
Drug: Provisional drug
RxNorm normalized name: Clearskin Professional Daily Correcting
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Provisional drug use
Trial: 16824849
Drug: Provisional GPIIb/IIIa
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Provisional GPIIb/IIIa inhibitor
Trial: 26289163
Drug: Chronic seton
RxNorm normalized name: Chromic Chloride
DrugBank: Chromic chloride (DB09129)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chronic seton drainage with oral 6-mercaptopurine (6MP) for one year
Trial: 26289163
Drug: Anti-TNF medication
RxNorm normalized name: pramoxine hydrochloride Medicated Pad [Scalpicin Anti-Itch]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-TNF medication with 6MP for one year (seton removal after six weeks)
Trial: 23048177
Drug: Standard smoking
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard smoking cessation intervention (individual counseling and nicotine replacement therapies)
Trial: 23048177
Drug: Nicotine replacement
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nicotine replacement therapies
Trial: 16294574
Drug: Antibiotic ointment
RxNorm normalized name: CVS Antibiotic Ointment
DrugBank: Polymyxin B (DB00781)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Antibiotic ointment and dry clean dressing (DCD)
Trial: 24449819
Drug: Transendocardial stem
RxNorm normalized name: stem bromelain
DrugBank: Stem bromelain (DB12249)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transendocardial stem cell injection (TESI) with mesenchymal stem cells
Trial: 21950372
Drug: Pregabalin (75mg-300mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pregabalin (75mg-300mg twice a day)
Trial: 12681871
Drug: Oral misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral misoprostol (100 microg) every 4 hours for a maximum of two doses
Trial: 10382948
Drug: G‐CSF starting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G‐CSF starting on day 8
Trial: 10382948
Drug: G‐CSF starting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G‐CSF starting on day 15
Trial: 9124979
Drug: Cefpirome administered
RxNorm normalized name: Cefpirome
DrugBank: Cefpirome (DB13682)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefpirome administered by slow intravenous infusion in a daily dose of 2 to 4 g every 12 hours depending on the disease severity.
Trial: 9124979
Drug: Cefpirome therapy
RxNorm normalized name: Cefpirome
DrugBank: Cefpirome (DB13682)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefpirome therapy for exacerbated severe chronic purulent bronchitis.
Trial: 9124979
Drug: Cefpirome treatment
RxNorm normalized name: Cefpirome
DrugBank: Cefpirome (DB13682)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefpirome treatment for mucoviscidosis.
Trial: 1829078
Drug: Teicoplanin and
RxNorm normalized name: teicoplanin
DrugBank: Teicoplanin (DB06149)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Teicoplanin and ceftriaxone combination therapy (arm A)
Trial: 1829078
Drug: Tri-antibiotic regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tri-antibiotic regimen (teicoplanin, ceftriaxone, amikacin) when fever occurred (arm B)
Trial: 6871920
Drug: Sustained-release quinidine
RxNorm normalized name: quinidine Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained-release quinidine gluconate
Trial: 6871920
Drug: Sustained-release quinidine
RxNorm normalized name: quinidine Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained-release quinidine sulfate
Trial: 29806538
Drug: BAY 1158061
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BAY 1158061 (30 mg at 14-day interval)
Trial: 29806538
Drug: BAY 1158061
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BAY 1158061 (60 mg at 28-day interval)
Trial: 29806538
Drug: BAY 1158061
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BAY 1158061 (90 mg at 14-day interval)
Trial: 26446239
Drug: Ramucirumab in
RxNorm normalized name: ramucirumab Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ramucirumab in combination with docetaxel
Trial: 26446239
Drug: Placebo in
RxNorm normalized name: placebo INTRAVEN VIAL (ML)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo in combination with docetaxel
Trial: 19302639
Drug: Epidural saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural saline washout (30 ml saline)
Trial: 17969888
Drug: TCM therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TCM therapy according to syndrome differentiation combined with Western medicine
Trial: 17969888
Drug: Western medicine
RxNorm normalized name: Medicaine Sting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Western medicine by staging
Trial: 10858688
Drug: Self-administered glycerine
RxNorm normalized name: Glycerin
DrugBank: Glycerin (DB09462)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-administered glycerine suppository
Trial: 30169547
Drug: 100mg Nimesulide
RxNorm normalized name: nimesulide 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100mg Nimesulide immediate, intermediate and slow release tablets
Trial: 10651671
Drug: Intrathecal morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal morphine (75 or 100 microg) combined with 5 mg of isobaric bupivacaine
Trial: 10651671
Drug: Subcutaneous saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous saline solution (control group)
Trial: 10651671
Drug: Intrathecal morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal morphine combined with bupivacaine
Trial: 8878142
Drug: Oral supplements
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral supplements (OS)
Trial: 2004961
Drug: 3D treatment
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 3D treatment planning (19.8 Gy boost of a total 70.2 Gy treatment schedule)
Trial: 2004961
Drug: 3D treatment
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 3D treatment planning
Trial: 2004961
Drug: 2D treatment
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2D treatment planning
Trial: 15848557
Drug: 720 mg
RxNorm normalized name: pancreatin 720 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 720 mg of oral enteric-coated mycophenolate sodium (E-MPS)
Trial: 12669777
Drug: Pamidronate 90
RxNorm normalized name: pamidronate 90 mg intravenous powder for injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pamidronate 90 mg via 2-hour intravenous infusion every 3 to 4 weeks for 12 months
Trial: 12669777
Drug: Zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Zoledronic acid 4 mg via 15-minute intravenous infusion every 3 to 4 weeks for 12 months
Trial: 12669777
Drug: Zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Zoledronic acid 8 mg via 15-minute intravenous infusion every 3 to 4 weeks for 12 months
Trial: 12080961
Drug: Active treatment
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active treatment (microwave thermotherapy with the Dornier Urowave)
Trial: 7667816
Drug: Enoxaparin, 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoxaparin, 20 mg per day for one month
Trial: 7667816
Drug: Moroxydine chloride,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moroxydine chloride, 1200 mg per day for one month
Trial: 6969625
Drug: Oral BCG
RxNorm normalized name: Tice BCG Topical Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral BCG immunotherapy
Trial: 21702128
Drug: Tropisetron (alpha7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tropisetron (alpha7 nAchR agonist and 5‐HT3 receptor antagonist)
Trial: 18643849
Drug: 4-hour patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4-hour patch application of PD P 506 A
Trial: 18643849
Drug: 2-hour patch
RxNorm normalized name: nitroglycerin
DrugBank: Nitroglycerin (DB00727)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2-hour patch application of PD P 506 A
Trial: 18643849
Drug: 1-hour patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1-hour patch application of PD P 506 A
Trial: 18643849
Drug: 0.5-hour patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5-hour patch application of PD P 506 A
Trial: 17536077
Drug: Adjustment for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjustment for factors affecting glycemia (age, sex, education, marital status, blood pressure, adiposity, hematocrit, fasting and post-glucose load glucose levels, glucose area under the curve, beta-cell function, insulin resistance)
Trial: 15978303
Drug: Cetirizine (10-mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cetirizine (10-mg tablets once daily)
Trial: 12706362
Drug: Boost dose
RxNorm normalized name: BOOST
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Boost dose for patients ≤40 years
Trial: 10589637
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of levobupivacaine 0.25% and morphine 0.005%
Trial: 10589637
Drug: Morphine 0.005%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine 0.005%
Trial: 10163386
Drug: High-dose epinephrine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose epinephrine (HDE) - 5, 10, and 15 mg boluses to a total dose of 30 mg
Trial: 10163386
Drug: Standard-dose epinephrine
RxNorm normalized name: epinephrine Metered Dose Inhaler
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-dose epinephrine (SDE) - 1.0 mg boluses to a maximum dose of 4 mg
Trial: 1678965
Drug: Bisoprolol (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bisoprolol (5 mg once a day)
Trial: 1678965
Drug: Propranolol (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (10 mg three times a day)
Trial: 6351901
Drug: Oral atenolol
RxNorm normalized name: Atenolol
DrugBank: Atenolol (DB00335)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral atenolol 25 mg twice daily